Clinical Trials
5 trialsNCT03547154 2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00264160 2017-03-06
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
Novartis
Phase 2/3 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
NCT02103322 2014-06-27
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
Amneal Pharmaceuticals, LLC
Phase 2/3 Completed